How large is the gonadotropin-releasing hormone (gnrh) agonist market, and what is its growth trajectory?
The gonadotropin-releasing hormone (GnRH) agonist market size has grown steadily in recent years. It will grow from $4.1 billion in 2024 to $4.23 billion in 2025 at a compound annual growth rate (CAGR) of 3.2%. The growth in the historic period can be attributed to rising awareness and diagnosis of hormonal disorders, increasing prevalence of hormone-related diseases, increasing prevalence of prostate cancer, growing awareness about hormone therapy, increase demand for long-term safety and efficacy.
The gonadotropin-releasing hormone (GnRH) agonist market size is expected to see steady growth in the next few years. It will grow to $4.72 billion in 2029 at a compound annual growth rate (CAGR) of 2.8%. The growth in the forecast period can be attributed to rising awareness and early diagnosis, rising healthcare expenditure, increasing use in fertility treatments, rising demand for personalized medicine, and increasing research funding and grants. Major trends in the forecast period include advancements in drug delivery systems, advancements in oncology and reproductive medicine, growing demand for hormone therapy options, increasing research and development, and rise of long-acting formulations.
Get Your Free Sample of The Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18814&type=smp
What have been the primary factors driving the gonadotropin-releasing hormone (gnrh) agonist market’s growth?
The increasing prevalence of hormone-related diseases is expected to propel the growth of the gonadotropin-releasing hormone (GnRH) agonist market going forward. Hormone-related disorders are medical conditions caused by imbalances or dysfunctions in the endocrine system, which produces and regulates hormones. It includes diseases such as diabetes, hyperthyroidism, and prostate cancer. The rising incidence of hormone-related diseases are caused due to environmental factors, obesity and metabolic syndrome, genetics, and the aging population. Gonadotropin-releasing hormone (GnRH) agonists carefully manage hormone levels and offer a tailored approach to treating problems associated with hormonal imbalances and dependent diseases. For instance, In December 2023, the Australian Bureau of Statistics reported that in 2022, approximately one in twenty people, or 5.3% (around 1.3 million individuals), were living with diabetes. The prevalence of diabetes was similar among genders, with rates of 5.8% for males and 4.9% for females. Additionally, diabetes was the seventh leading cause of death in Australia, accounting for 6,050 fatalities in that year. Therefore, the increasing prevalence of hormone-related diseases is driving the growth of the gonadotropin-releasing hormone (GnRH) agonist market.
What are the key segments within the gonadotropin-releasing hormone (gnrh) agonist market?
The gonadotropin-releasing hormone (GnRH) agonist market covered in this report is segmented –
1) By Type: Leuprorelin, Goserelin, Taltirelin, Histrelin, Other Types
2) By Formulation: Injectable, Implants, Oral, Nasal Sprays
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Prostate Cancer, Breast Cancer, Endometriosis, Uterine Fibroids, Precocious Puberty, Fertility Treatment, Other Applications
5) By End-User: Hospital, Specialty Clinics, Ambulatory Surgical Centers (ASCs), Other End-Users
Subsegments:
1) By Leuprorelin: Injectable Leuprorelin, Implantable Leuprorelin
2) By Goserelin: Goserelin Injection, Goserelin Implant
3) By Taltirelin: Injectable Taltirelin, Oral Taltirelin
4) By Histrelin: Histrelin Implant, Histrelin Injection
5) By Other Type: Triptorelin, Buserelin, Nafarelin
Order your report now for swift delivery
Which key players are shaping the gonadotropin-releasing hormone (gnrh) agonist market?
Major companies operating in the gonadotropin-releasing hormone (GnRH) agonist market are Pfizer Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Sandoz Group AG, Ipsen Pharma, Aurobindo Pharma Limited, Cipla Limited, Dr Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., Ferring Pharmaceuticals, Amneal Pharmaceuticals Inc., Endo International plc, Lupin Limited, Gland Pharma Limited, Glenmark Pharmaceuticals Ltd., Zydus Lifesciences Limited, Bachem Holding AG, Tolmar Pharmaceuticals Inc., Debiopharm Group, Sun Pharmaceutical Industries Ltd.
How will emerging trends drive the gonadotropin-releasing hormone (gnrh) agonist market throughout the forecast period?
Major companies operating in the gonadotropin-releasing hormone (GnRH) agonist market are developing advanced androgen deprivation therapy drugs to enhance the effectiveness and precision of treatment for hormone-sensitive cancers. androgen deprivation therapy (ADT) drugs, including gonadotropin-releasing hormone (GnRH) analogs, reduce or eliminate androgen levels to slow or halt hormone-sensitive cancer growth. For instance, in January 2024, Zydus Lifesciences Limited, an India-based pharmaceutical company, launched Relugolix under the brand name Rexigo. It is India’s first and only once-daily oral therapy for testosterone suppression in advanced prostate cancer, eliminating the need for injectable treatments. This convenient oral option features Relugolix, a globally recognized active ingredient that delivers rapid testosterone suppression. Rexigo is 50% more affordable than existing injectable alternatives for advanced prostate cancer in India. Its introduction represents a major advancement in prostate cancer care, offering a safe, effective, and user-friendly treatment choice for both patients and healthcare providers.
How do regional factors impact the gonadotropin-releasing hormone (gnrh) agonist market, and which region is the largest contributor?
North America was the largest region in the gonadotropin-releasing hormone (GnRH) agonist market in 2024. The regions covered in the gonadotropin-releasing hormone (GnRH) agonist market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Gonadotropin-Releasing Hormone (GnRH) Agonist Market Report 2025 Offer?
The gonadotropin-releasing hormone (gnrh) agonist market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Gonadotropin-releasing hormone (GnRH) agonists are synthetic agents that replicate the action of natural GnRH, which triggers the pituitary gland to release follicle-stimulating hormone (FSH) and luteinizing hormone (LH). These agonists are used to manage hormonal imbalances by controlling hormone levels. They are particularly useful in fertility treatments to regulate and prevent premature ovulation during procedures like in vitro fertilization.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18814
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
